Zacks Investment Research cut shares of Mast Therapeutics Inc (NASDAQ:MSTX) from a buy rating to a hold rating in a report released on Wednesday.
According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “
A number of other equities research analysts also recently commented on MSTX. Maxim Group restated a buy rating and issued a $5.00 price objective on shares of Mast Therapeutics in a research report on Tuesday, July 12th. Roth Capital reaffirmed a buy rating and issued a $2.00 target price on shares of Mast Therapeutics in a report on Friday, July 15th. Canaccord Genuity reaffirmed a buy rating and issued a $3.00 target price on shares of Mast Therapeutics in a report on Thursday, July 28th. Laidlaw cut shares of Mast Therapeutics from a buy rating to a neutral rating in a report on Wednesday, September 21st. Finally, Cowen and Company cut shares of Mast Therapeutics from an outperform rating to a market perform rating in a report on Friday, September 23rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Mast Therapeutics presently has a consensus rating of Hold and an average price target of $2.07.
Mast Therapeutics (NASDAQ:MSTX) traded up 11.6250% during midday trading on Wednesday, reaching $0.0893. The company’s stock had a trading volume of 3,764,825 shares. The company’s 50-day moving average is $0.32 and its 200 day moving average is $0.36. Mast Therapeutics has a 52 week low of $0.08 and a 52 week high of $0.71. The firm’s market capitalization is $18.92 million.
Mast Therapeutics (NASDAQ:MSTX) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. Analysts expect that Mast Therapeutics will post ($0.19) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent quarter.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.